Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: Longer survival with larger size tumors

Urology

Volumn 55, Issue 4, 2000, Pages 495-500

  Tsuchiya, Kiyotaka ^a,b,c,d   Uchida, Tatsuya ^a,b,c,d   Kobayashi, Mikio ^e   Maeda, Hiroshi ^a,b,c,d   Konno, Toshimitsu ^c   Yamanaka, Hidetoshi ^a,b,c,d  

^a GUNMA UNIVERSITY   (Japan)

^b Isesaki Municipal Hospital   (Japan)

^c Depts of Department of Microbiology   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED POPPYSEED OIL; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ADULT; AGED; ARTICLE; BACKACHE; DRUG EFFICACY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL; SURVIVAL RATE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; KIDNEY NEOPLASMS; MALE; MALEIC ANHYDRIDES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYSTYRENES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ZINOSTATIN;

EID: 0034099397     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00537-3     Document Type: Article

References (23)

1. Neidhart J.A. Interferon therapy for the treatment of renal cancer. Cancer. 57:1986;1696-1699.
2. Figlin R.A., Abi-Aad A.S., Belldegrun A., et al. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal call carcinoma. Semin Oncol. 18:1991;102-107.
3. Sella A., Logothetic C.J., Fitz K., et al. Phase study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol. 147:1992;573-577.
4. Almgard L.E., Feuderson I., Haverling M., et al. Treatment of renal adenocarcinoma by embolic occlusion of the renal circulation. Br J Urol. 45:1973;474-477.
5. Maeda H., Ueda M., Morinaga T., et al. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin pronounced improvements in pharmacological properties . J Med Chem. 28:1985;455-461.
6. Maeda H., Matsumoto T., Konno T., et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting a brief review on SMANCS . J Protein Chem. 3:1984;181-193.
7. Konno T., Maeda H., Iwai K., et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 54:1984;2367-2373.
8. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 6:1989;193-210.
9. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor enhanced therapeutic effect and x-ray image . Cancer Res. 44:1984;2115-2121.
10. Konno T., Maeda H., Iwai K., et al. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma a preliminary report . Eur J Cancer Clin Oncol. 19:1983;1053-1065.
11. Ohtsuka N., Konno T., Miyauchi Y., et al. Anticancer effects of arterial administration of the anticancer agent SMANCS with Lipiodol on metastatic lymph nodes. Cancer. 59:1987;1560-1565.
12. Kobayashi M., Maeda H., Imai K., et al. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology. 37:1991;288-294.
13. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assn. 53:1958;457.
14. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumours. 1997;180-182 John Wiley & Sons, New York.
15. Robson C.J., Churchill B.M., Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 101:1969;297-301.
16. Maki S., Konno T., Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer. 56:1985;751-757.
17. Suzuki F, and Kobayashi M: Immunomodulating antitumor mechanisms of SMANCS, in Maeda H, Edo K, and Ishida N (Eds): Neocarzinostatin. Tokyo, Springer-Verlag, 1997, pp 167-186.
18. Masuda E, and Maeda H: Host-mediated antitumor activity induced by neocarzinostatin and its polymer-conjugated derivative SMANCS in tumor-bearing mice, in Maeda H, Edo K, and Ishida N (Eds): Neocarzinostatin. Tokyo, Springer-Verlag, 1997, pp 187-204.
19. Thompson I.M., Peek M. Improvement in survival of patients with renal cell carcinoma - The role of the serendipitously detected tumor. J Urol. 140:1988;487-490.
20. Tsukamoto T., Kumamoto Y., Takahashi A., et al. Tumor size of renal cell carcinoma its clinical implication . Urol Int. 48:1992;378-383.
21. Guinan P.D., Vogelzang N.J., Fremgen A.M., et al. Renal cell carcinoma tumor size, stage and survival . J Urol. 153:1995;901-903.
22. Trinchet J.C. A comparison of Lipiodol chemoembolization and conservation treatment for uresectable hepatocellular carcinoma. New Engl J Med. 332:1995;1256-1261.
23. Kurita M., Nakamura T., Kato H., et al. Intraarterial therapy with SMANCS/Lpd and subsequent partial hepatectomy in patient with postoperation of renal cell carcinoma . Jpn J Clin Urol. 45:1991;861-863.